ArticleFrontiers in pharmacology2025
Natural products in treating diabetic kidney disease: a visualized bibliometric analysis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tetrahydropalmatine may alleviate doxorubicin-induced renal injury by activating the Sirt3-mediated Nrf2/HO-1 pathway.Biology direct · 2026Article
- Tadehagi triquetrum aqueous extract ameliorates diabetic kidney disease through mitigating epithelial senescence via the PTEN/AKT/mTOR signaling pathway.Chinese medicine · 2026Article
- Gut microbiota-liver-kidney axis in diabetic kidney disease: mechanistic insights into amino acid metabolism and nutritional intervention strategies targeting natural bioactive compounds.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) is one of the most significant complications in diabetic patients, yet current therapeutic options are limited. The advantages of natural products in treating chronic diseases have increasingly garnered attention. This study aims to map the landscape of natural products in DKD and provide new insights for future research in this field. Methods: Literature retrieval was conducted through the Web of Science. CiteSpace and VOSviewer were employed to conduct visual analyses of these papers. Results: A total of 523 literature were obtained, originating from 655 institutions across 40 countries/regions and involving 3,116 authors. These literature were published in 178 journals. The results indicate that China leads in this field, with Li Ping contributing the most publications. Zhang Lei's work has been cited the most. Journal of Ethnopharmacology is the most popular journal. The paper with the highest average annual citation rate is authored by Tang, GY. Keyword analysis reveals that systematic biological approaches such as network pharmacology, molecular docking, and gut microbiota have become hotspots in this field. Conclusion: Natural products exhibit positive pharmacological activity and therapeutic value in the treatment of DKD. Extensive cooperation and communication among countries, institutions, and authors still need to be strengthened to promote basic research and clinical applications of natural products. Besides, the deep integration of network pharmacology with artificial intelligence and big data represents a hot topic and trend in future research on natural products against DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.